Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 973.52 Thousand USD | 19.63% |
| 2023 | 813.79 Thousand USD | -29.48% |
| 2022 | 1.15 Million USD | 15.17% |
| 2021 | 1 Million USD | -2.9% |
| 2020 | 1.03 Million USD | -18.7% |
| 2019 | 1.26 Million USD | 63.38% |
| 2018 | 776.79 Thousand USD | 14.99% |
| 2017 | 675.55 Thousand USD | 58.74% |
| 2016 | 425.58 Thousand USD | 8.42% |
| 2015 | 392.53 Thousand USD | -28.8% |
| 2014 | 551.3 Thousand USD | 102.33% |
| 2013 | 272.47 Thousand USD | 334.79% |
| 2012 | 62.66 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 863.31 Thousand USD | 6.08% |
| 2024 FY | 973.52 Thousand USD | 19.63% |
| 2024 Q2 | 917.99 Thousand USD | 6.33% |
| 2024 Q3 | 962.98 Thousand USD | 4.9% |
| 2024 Q4 | 973.52 Thousand USD | 1.1% |
| 2023 Q1 | 1.22 Million USD | 5.83% |
| 2023 Q2 | 1.26 Million USD | 3.42% |
| 2023 FY | 813.79 Thousand USD | -29.48% |
| 2023 Q4 | 813.79 Thousand USD | -37.47% |
| 2023 Q3 | 1.3 Million USD | 3.05% |
| 2022 Q1 | 1.01 Million USD | 1.62% |
| 2022 Q4 | 1.15 Million USD | 9.97% |
| 2022 Q3 | 1.04 Million USD | 0.24% |
| 2022 FY | 1.15 Million USD | 15.17% |
| 2022 Q2 | 1.04 Million USD | 2.81% |
| 2021 Q2 | 967.82 Thousand USD | -7.68% |
| 2021 FY | 1 Million USD | -2.9% |
| 2021 Q3 | 987.92 Thousand USD | 2.08% |
| 2021 Q4 | 1 Million USD | 1.42% |
| 2021 Q1 | 1.04 Million USD | 1.59% |
| 2020 Q1 | 1.29 Million USD | 1.7% |
| 2020 Q3 | 1.01 Million USD | -9.78% |
| 2020 FY | 1.03 Million USD | -18.7% |
| 2020 Q4 | 1.03 Million USD | 2.15% |
| 2020 Q2 | 1.11 Million USD | -13.26% |
| 2019 Q2 | 904 Thousand USD | 9.19% |
| 2019 Q3 | 982.75 Thousand USD | 8.71% |
| 2019 Q4 | 1.26 Million USD | 29.14% |
| 2019 FY | 1.26 Million USD | 63.38% |
| 2019 Q1 | 827.89 Thousand USD | 6.58% |
| 2018 Q2 | 729.44 Thousand USD | 8.01% |
| 2018 Q3 | 747.03 Thousand USD | 2.41% |
| 2018 Q4 | 776.79 Thousand USD | 3.98% |
| 2018 FY | 776.79 Thousand USD | 14.99% |
| 2018 Q1 | 675.33 Thousand USD | -0.03% |
| 2017 Q3 | 588.42 Thousand USD | 16.92% |
| 2017 Q4 | 675.55 Thousand USD | 14.81% |
| 2017 FY | 675.55 Thousand USD | 58.74% |
| 2017 Q1 | 437.89 Thousand USD | 2.89% |
| 2017 Q2 | 503.27 Thousand USD | 14.93% |
| 2016 Q1 | 411.05 Thousand USD | 4.72% |
| 2016 FY | 425.58 Thousand USD | 8.42% |
| 2016 Q4 | 425.58 Thousand USD | 20.75% |
| 2016 Q3 | 352.43 Thousand USD | -25.65% |
| 2016 Q2 | 474.04 Thousand USD | 15.32% |
| 2015 Q1 | 529.5 Thousand USD | -3.96% |
| 2015 Q4 | 392.53 Thousand USD | -24.0% |
| 2015 FY | 392.53 Thousand USD | -28.8% |
| 2015 Q3 | 516.52 Thousand USD | -27.76% |
| 2015 Q2 | 714.99 Thousand USD | 35.03% |
| 2014 Q4 | 551.3 Thousand USD | 158.57% |
| 2014 FY | 551.3 Thousand USD | 102.33% |
| 2014 Q1 | 496.4 Thousand USD | 82.18% |
| 2014 Q2 | 498.86 Thousand USD | 0.5% |
| 2014 Q3 | 213.21 Thousand USD | -57.26% |
| 2013 Q4 | 272.47 Thousand USD | 43.98% |
| 2013 FY | 272.47 Thousand USD | 334.79% |
| 2013 Q2 | 179.77 Thousand USD | 28.55% |
| 2013 Q3 | 189.24 Thousand USD | 5.27% |
| 2013 Q1 | 139.85 Thousand USD | 123.16% |
| 2012 Q2 | 600.00 USD | 0.0% |
| 2012 Q4 | 62.66 Thousand USD | 7675.19% |
| 2012 FY | 62.66 Thousand USD | 0.0% |
| 2012 Q3 | 806.00 USD | 34.33% |
| 2012 Q1 | 600.00 USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -3448.752% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 89.715% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.657% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -20.368% |
| Rebus Holdings, Inc. | 5.24 Million USD | 81.428% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.35% |
| Qrons Inc. | 1.48 Million USD | 34.606% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 20.607% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.701% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2078.112% |
| Skye Bioscience, Inc. | 14.07 Million USD | 93.082% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.174% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 89.84% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -130.93% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.054% |
| Intellipharmaceutics International Inc. | 12 Million USD | 91.893% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 74.723% |
| Mesoblast Limited | 188.44 Million USD | 99.483% |
| Marizyme, Inc. | 26.67 Million USD | 96.351% |
| Genus plc | 485 Million USD | 99.799% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 83.337% |
| Pharming Group N.V. | 244.07 Million USD | 99.601% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 51.569% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 61.312% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 74.381% |
| ContraFect Corporation | 32.53 Million USD | 97.007% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 50.864% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 74.566% |
| IMV Inc. | 37.93 Million USD | 97.434% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 91.734% |
| MultiCell Technologies, Inc. | 1617.67 USD | -60080.939% |
| ONE Bio Corp. | 27.49 Million USD | 96.459% |
| Accustem Sciences Inc. | 1.07 Million USD | 9.795% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.742% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 53.972% |
| Q BioMed Inc. | 8.13 Million USD | 88.03% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.826% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 81.082% |
| Biomind Labs Inc. | 1.49 Million USD | 35.038% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.18% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 89.233% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 94.71% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 32.104% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -585.125% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -384.063% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 83.057% |
| GB Sciences, Inc. | 5.41 Million USD | 82.03% |
| Alpha Cognition Inc. | 7.16 Million USD | 86.412% |
| HST Global, Inc. | 593.59 Thousand USD | -64.006% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 22.686% |
| Halberd Corporation | 728.71 Thousand USD | -33.595% |
| Enzolytics Inc. | 365.26 Million USD | 99.733% |
| Agentix Corp. | 2.51 Million USD | 61.223% |
| Resverlogix Corp. | 67.39 Million USD | 98.556% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -16.072% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.781% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 43.201% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 96.066% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 91.821% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 73.438% |
| AVAX Technologies, Inc. | 3.99 Million USD | 75.624% |
| Zenith Capital Corp. | 27.56 Thousand USD | -3431.245% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.927% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -307.925% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 73.93% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -42.991% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 64.098% |
| Kadimastem Ltd | 3.5 Million USD | 72.224% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1354.57% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.063% |
| BioStem Technologies, Inc. | 15.9 Million USD | 93.879% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -109.497% |
| LadRx Corporation | 2.2 Million USD | 55.759% |
| Cell Source, Inc. | 15.8 Million USD | 93.841% |
| Regen BioPharma, Inc. | 5.45 Million USD | 82.162% |
| Regen BioPharma, Inc. | 5.45 Million USD | 82.162% |
| NovAccess Global Inc. | 7.86 Million USD | 87.615% |
| Affymax, Inc. | 8.87 Million USD | 89.026% |
| Itoco Inc. | 1.65 Million USD | 41.111% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 52.547% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 83.906% |
| Mobile Lads Corp. | 1.31 Million USD | 25.883% |
| CytoDyn Inc. | 127.89 Million USD | 99.239% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2229.072% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 37.848% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 91.186% |
| SYBLEU INC | 681.41 Thousand USD | -42.869% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 84.045% |
| International Stem Cell Corporation | 5.27 Million USD | 81.551% |
| Bioxytran, Inc. | 3.24 Million USD | 70.041% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -55.563% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 78.915% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 97.625% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 95.628% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 51.934% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 82.228% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 96.645% |
| PureTech Health plc | 125.58 Million USD | 99.225% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 74.088% |
| IXICO plc | 1.9 Million USD | 48.77% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 95.258% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.058% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Cellectis S.A. | 249.36 Million USD | 99.61% |